Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AbCellera BiologicsABCL +3.60%53 3-Year EPS without NRI Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates ABCL with a GF Score™ of 53/100 and a GF Value™ of $4.92 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,160 Biotechnology companies, AbCellera Biologics ranks worse than 86206.81% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of AbCellera Biologics was 442.90% per year. The lowest was 442.90% per year. And the median was 442.90% per year.
AbCellera Biologics (NAS:ABCL) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
AbCellera Biologics 3-Year EPS without NRI Growth Rate Related Terms
ABCL vs ANAB, MLTX, SRPT: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, AbCellera Biologics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's 3-Year EPS without NRI Growth Rate falls into.
AbCellera Biologics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 0.00% mean?
AbCellera Biologics (ABCL) has a 3-Year EPS without NRI Growth Rate of 0.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for AbCellera Biologics and its competitors. Over the past decade, AbCellera Biologics' 3-Year EPS without NRI Growth Rate has ranged from 442.90 to 442.90. According to the industry distribution chart, AbCellera Biologics ranks #999999 out of 1160 companies in the Biotechnology industry.
Is AbCellera Biologics' 3-Year EPS without NRI Growth Rate too high?
AbCellera Biologics' current 3-Year EPS without NRI Growth Rate is 0.00%. Over the past 10 years, this metric has ranged from a low of 442.90 to a high of 442.90. Based on the distribution chart, AbCellera Biologics ranks #999999 out of 1160 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AbCellera Biologics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' 3-Year EPS without NRI Growth Rate compare to ANAB and MLTX?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #999999 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places AbCellera Biologics in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Historically, AbCellera Biologics' own 3-Year EPS without NRI Growth Rate has ranged from 442.90 to 442.90 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for AbCellera Biologics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current 3-Year EPS without NRI Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.92, compared to a current price of $11.38 — trading 131.3% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 0.00%. AbCellera Biologics' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current 3-Year EPS without NRI Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $11.38 is trading 131.3% above its estimated GF Value™ of $4.92.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
3-Year EPS without NRI Growth Rate: 0.00%
GF Value™: $4.92 vs. price of $11.38 (131.3% above fair value)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
53GF Score
Get the complete analysis for ABCL
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
